Search Result

Results for "

immune checkpoint inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Checkpoint Kinase (Chk) (1) Amyloid-β (1) Apoptosis (2) Bcl-2 Family (1) C-type Lectin-like Receptors (CTLRs) (1) Cadherin (1) CaMK (1) Caspase (1) CCR (1) CD28 (2) CD47 (1) CD73 (1) CTLA-4 (1) Cytochrome P450 (1) DGK (1) DNA Stain (1) Drug Intermediate (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) ERK (2) Eukaryotic Initiation Factor (eIF) (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (1) IFNAR (2) IKZF Family (4) Integrin (1) Interleukin Related (1) JNK (1) LAG-3 (1) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (2) LILRB (1) METTL3 (1) Mitochondrial Metabolism (1) MMP (1) Molecular Glues (4) Necroptosis (1) Opioid Receptor (1) p38 MAPK (2) Parasite (1) PD-1/PD-L1 (22) PI3K (1) Potassium Channel (1) Prostaglandin Receptor (1) Reference Standards (2) RIP kinase (1) Sodium Channel (1) STAT (1) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (2) Tau Protein (1) TNF Receptor (1) Transmembrane Glycoprotein (5) VEGFR (1)
By Research Areas:	Cancer (51) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (23) Neurological Disease (2)

By Targets:

Checkpoint Kinase (Chk) (1)

Amyloid-β (1)

Apoptosis (2)

Bcl-2 Family (1)

C-type Lectin-like Receptors (CTLRs) (1)

Cadherin (1)

CaMK (1)

Caspase (1)

CCR (1)

CD28 (2)

CD47 (1)

CD73 (1)

CTLA-4 (1)

Cytochrome P450 (1)

DGK (1)

DNA Stain (1)

Drug Intermediate (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

ERK (2)

Eukaryotic Initiation Factor (eIF) (1)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (1)

IFNAR (2)

IKZF Family (4)

Integrin (1)

Interleukin Related (1)

JNK (1)

LAG-3 (1)

Ligands for E3 Ligase (3)

Ligands for Target Protein for PROTAC (2)

LILRB (1)

METTL3 (1)

Mitochondrial Metabolism (1)

MMP (1)

Molecular Glues (4)

Necroptosis (1)

Opioid Receptor (1)

p38 MAPK (2)

Parasite (1)

PD-1/PD-L1 (22)

PI3K (1)

Potassium Channel (1)

Prostaglandin Receptor (1)

Reference Standards (2)

RIP kinase (1)

Sodium Channel (1)

STAT (1)

TAM Receptor (1)

Target Protein Ligand-Linker Conjugates (2)

Tau Protein (1)

TNF Receptor (1)

Transmembrane Glycoprotein (5)

VEGFR (1)

By Research Areas:

Cancer (51)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (23)

Neurological Disease (2)

Inhibitors & Agonists

Screening-Bibliotheken

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Checkpoint Kinase (Chk) Serpin

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-156677

STC-15 4 Publications Verification	METTL3	Cancer
STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P9986

Tiragolumab MTIG-7192A; RG-6058	CD28	Cancer
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .

HY-102011

BMS-1166 Maximum Cited Publications 6 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-101093

CA-170 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .

HY-152293

EVT801	VEGFR ERK	Cancer
EVT801 is an orally active and selective inhibitor of VEGFR-3 (IC₅₀=11 nM), which has antitumor effects. EVT801 inhibits not only VEGF-C-induced human endothelial cell proliferation, but also tumor (lymphatic) angiogenesis in tumor mouse models. EVT801 can reduce tumor hypoxia, immunosuppressive cytokines (CCL4, CCL5) and myeloid derived suppressor cells (MDSC) production. EVT801 has synergistic effect with immune checkpoint therapy (ICT), which improves ICT response rate and has better inhibitory effect on cancer mouse models . EVT801 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P99032

Monalizumab 5 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99950

Evorpacept ALX148	CD47	Cancer
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-N6579

Arvenin I	p38 MAPK Mitochondrial Metabolism	Cancer
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway . Arvenin I exhibits broad-spectrum antiproliferative against cancer cells . Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice . Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer ^[1][2].

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-156649

Vorbipiprant CR6086	Prostaglandin Receptor Interleukin Related MMP PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Vorbipiprant (CR6086) is an orally active EP4 receptor antagonist with high selectivity for the human EP4 receptor (K_i: 16.6 nM). Vorbipiprant has immunomodulatory, anti-inflammatory, antitumor, and anti-angiogenic activities. Vorbipiprant can inhibit the expression of multiple pro-inflammatory cytokines and the activation of immune cells, and convert "cold" tumors unresponsive to immune checkpoint inhibitors into "hot" tumors. Vorbipiprant is used in the research of diseases such as rheumatoid arthritis and colon cancer .

HY-P991480

ONC-841	Transmembrane Glycoprotein Tau Protein Amyloid-β	Neurological Disease Cancer
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .

HY-120635

BMS-1001 hydrochloride	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC₅₀ value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .

HY-150879

BMS-37	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor with an IC₅₀ towards the PD-L1/PD-1 complex in the range of 18 to 200 nM. BMS-37 shows unspecific toxicity against modified Jurkat T cells with an EC₅₀ between 3 and 6 µM. BMS-37 can be used for the study of the PD-L1-induced exhaustion of T-cells or as PD-L1 ligand to synthesize PROTAC molecules .

HY-P990704

Rilvegostomig AZD-2936	PD-1/PD-L1 Transmembrane Glycoprotein	Cancer
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .

HY-122542A

PPACK dihydrochloride 2 Publications Verification Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-159647

PLX-4545	Molecular Glues Ligands for E3 Ligase IKZF Family	Cancer
PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PLX-4545 binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-156871

CAMK1D-IN-1	CaMK	Cancer
CAMK1D-IN-1 (compound I) is an inhibitor of CAMK1D, targeting cytotoxic T lymphocyte (CTL)-resistant tumor cells. CAMK1D impairs CTL-induced death receptor signaling and apoptosis by inhibiting caspases, making it a key and effective target for PD-L1-refractory tumors .

HY-131386A

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride	Target Protein Ligand-Linker Conjugates	Cancer
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1?(HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM .

HY-172930

PVTX-405	Molecular Glues IKZF Family Potassium Channel	Inflammation/Immunology Cancer
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn ^391V C57BL/6 mice .

HY-149667

BMS-332	DGK	Cancer
BMS-332 is a dual DGKα/ζ lipid kinase inhibitor, with IC₅₀s of 5 and 1 nM against DGKα and DGKζ, respectively. BMS-332 enhances the antigen-specific T cell response. BMS-332 reduces the viral load in the liver and spleen when combined with anti-PD-1 in chronic infection models. BMS-332 can be used for the study of T cell immune checkpoint strategy .

HY-P990778

Xirestomig ATG-101	TNF Receptor PD-1/PD-L1	Inflammation/Immunology Cancer
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) .

HY-148305

PD-1/PD-L1-IN-28	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of PD-1/PD-L1 signaling pathway (IC₅₀=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity .

HY-141431

Cbl-b-IN-2	E1/E2/E3 Enzyme	Inflammation/Immunology Cancer
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent .

HY-145240

eIF4E-IN-1	Eukaryotic Initiation Factor (eIF)	Infection Cancer
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .

HY-120647

BMS-1001	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC₅₀ value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .

HY-145239

PD-1/PD-L1-IN-13	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC₅₀ value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 ⁺ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .

HY-162810

ICOS-IN-1	CD28	Others
ICOS-IN-1 (compound 9) is an inhibitor of the interaction between ICOS and ICOS-L (IC₅₀=29.38 μM) and has activity in recognizing immune checkpoints .

HY-102011A

BMS-1166 hydrochloride Maximum Cited Publications 6 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-153435

RIP1 kinase inhibitor 5	RIP kinase Necroptosis	Cancer
RIP1 kinase inhibitor 5 (example 1) is a potent inhibitor of RIP1, which is used as a checkpoint kinase to control tumor immunity . RIP1 kinase inhibitor 5 is similar with SIR1-365 (compound 13), which inhibits necrosis and iron death activity .

HY-176203

XC-12	CD73	Cancer
XC-12 is an orally active and potent small-molecule CD73 inhibitor (an immune checkpoint) with IC₅₀ values of 12.36 nM and 1.29 nM against soluble and membrane-bound CD73 forms, respectively. XC-12 is promising for research of cancers .

HY-P990031

Dargistotug M-6223	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .

HY-P990061

Polzastobart JTX 8064	LILRB Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HY-P990259

Anti-Mouse CD96 Antibody (3.3)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma .

HY-131187

BMS-1166-N-piperidine-COOH	Ligands for Target Protein for PROTAC	Cancer
BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1 . BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-175236

SF-9-2	PD-1/PD-L1 Apoptosis ERK JNK Cadherin p38 MAPK GSK-3 IFNAR Caspase Bcl-2 Family	Cancer
SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC₅₀ = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research .

HY-13735H

Quinacrine acetate Acriquine acetate	Parasite Sodium Channel DNA Stain Apoptosis	Cancer
Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-117161

ZINC05626394	Cytochrome P450	Cancer
ZINC05626394 is a cytochrome b5 reductase 3 inhibitor with activity by increasing nitric oxide bioavailability. ZINC05626394 may have potential applications in anti-cancer suppression, especially in combination with antibody drug conjugates (ADCs) and immune checkpoint inhibitors. The efficacy of ZINC05626394 may be limited by different mechanisms, including antigen-related resistance and failure of endocytosis .

HY-120646

BMS-242	PD-1/PD-L1	Others
BMS-242 is a small molecule PD-1/PD-L1 inhibitor with the activity of inhibiting the PD-1/PD-L1 interaction. BMS-242 can bind to the hydrophobic channel pocket between PD-L1 molecules, inhibit the PD-1/PD-L1 immune checkpoint pathway, and provide a new way for cancer inhibition.

HY-155675

TPPC	Drug Intermediate	Cancer
TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer .

HY-163844

PD-1/PD-L1-IN-49	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC₅₀ of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint .

HY-131386

BMS-1166-N-piperidine-CO-N-piperazine	Target Protein Ligand-Linker Conjugates	Cancer
BMS-1166-N-piperidine-CO-N-piperazine incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1?(HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM .

HY-P992377

HY-0102	C-type Lectin-like Receptors (CTLRs)	Cancer
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .

HY-150879A

BMS-37 hydrochloride	PD-1/PD-L1	Cancer
BMS-37 hydrochloride is a PD-1/PD-L1 immune checkpoint inhibitor with an IC₅₀ towards the PD-L1/PD-1 complex in the range of 18 to 200 nM. BMS-37 hydrochloride shows unspecific toxicity against modified Jurkat T cells with an EC₅₀ between 3 and 6 µM. BMS-37 hydrochloride can be used for the study of the PD-L1-induced exhaustion of T-cells or as PD-L1 ligand to synthesize PROTAC molecules .

HY-102011R

BMS-1166 (Standard)	Reference Standards PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 (Standard) is the analytical standard of BMS-1166 (HY-102011). This product is intended for research and analytical applications. BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-101093R

CA-170 (Standard)	PD-1/PD-L1 Reference Standards	Inflammation/Immunology Cancer
CA-170 (Standard) is the analytical standard of CA-170 (HY-101093). This product is intended for research and analytical applications. CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .

HY-180900

Z3071585108	LAG-3	Inflammation/Immunology
Z3071585108 is a small molecule binder of the LAG-3 D1 domain with K_d values measured for the MST-TRIC channel and spectral shift detection of 59.2 and 56.1 μM respectively. Z3071585108 partially inhibits the binding of LAG-3 to MHCII, with an EC₅₀ of 42.9 μM. Z3071585108 can be used for the study of small molecule immunotherapies targeting LAG-3 .

Art. -Nr.	Produktname

HY-L031

Small Molecule Immuno-Oncology Compound Library

783 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L184

Anti-Gastric Cancer Compound Library

1,122 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 1,122 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Art. -Nr.	Produktname	Target	Research Area